(Q39042958)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24341883%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

title

In vitro assessment of the effects of anti-HER2 monoclonal antibodies on proliferation of HER2-overexpressing breast cancer cells (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24341883%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24341883%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Mahmood Jeddi-Tehrani

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24341883%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

author name string

Fathollah Tahmasebi

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24341883%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Tohid Kazemi

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24341883%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Jalal Khoshnoodi

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24341883%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Jafar Mahmoudian

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24341883%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Ali Ahmad Bayat

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24341883%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Hodjatallah Rabbani

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24341883%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Fazel Shokri

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24341883%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

publication date

1 January 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24341883%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24341883%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

volume

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24341883%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24341883%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

page(s)

43-49

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24341883%20AND%20SRC:MED&resulttype=core&format=json

Characterization of novel murine monoclonal antibodies directed against the extracellular domain of human HER2 tyrosine kinase receptor.

3 March 2020

cites work

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.156

The ErbB signaling network: receptor heterodimerization in development and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.156

In vivo activity of novel anti-ErbB2 antibody chA21 alone and with Paclitaxel or Trastuzumab in breast and ovarian cancer xenograft models

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.156

Anti-HER2 vaccines: new prospects for breast cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.156

Molecular analysis of signal transduction by growth factors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.156

Growth stimulation of A431 cells by epidermal growth factor: identification of high-affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.156

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.156

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.156

Trastuzumab: triumphs and tribulations

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.156

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.156

Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.156

Novel anti-HER2 monoclonal antibodies: synergy and antagonism with tumor necrosis factor-α.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.156

Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.156

Mechanisms of Resistance to Trastuzumab and Novel Therapeutic Strategies in HER2-Positive Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.156

p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.156

ErbB receptor activation, cell morphology changes, and apoptosis induced by anti-Her2 monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.156

Trastuzumab and pertuzumab produce changes in morphology and estrogen receptor signaling in ovarian cancer xenografts revealing new treatment strategies.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.156

Suppression and promotion of tumor growth by monoclonal antibodies to ErbB-2 differentially correlate with cellular uptake

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.156

Identification of epitope regions recognized by tumor inhibitory and stimulatory anti-ErbB-2 monoclonal antibodies: implications for vaccine design

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.156

Mechanistic aspects of the opposing effects of monoclonal antibodies to the ERBB2 receptor on tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.156

Defining the molecular response to trastuzumab, pertuzumab and combination therapy in ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.156

Monoclonal antibodies directed to the erbB-2 receptor inhibit in vivo tumour cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.156

Persistent elimination of ErbB-2/HER2-overexpressing tumors using combinations of monoclonal antibodies: relevance of receptor endocytosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.156

Synergistic down-regulation of receptor tyrosine kinases by combinations of mAbs: implications for cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.156

Structural analysis of the ErbB-2 receptor using monoclonal antibodies: Implications for receptor signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.156

Evaluation of known oncoantibodies, HER2, p53, and cyclin B1, in prediagnostic breast cancer sera

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.156

Vaccination with novel combinations of anti-HER2/neu cytokines fusion proteins and soluble protein antigen elicits a protective immune response against HER2/neu expressing tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.13.156

21 January 2018

Identifiers

DOI

10.2217/IMT.13.156

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24341883%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

1 reference